If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News -
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 - - Latest News -
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News

